Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 13/20 | 1.00 |
| ▸ | HTR1B | P28222 | 8/20 | 1.00 |
| ▸ | HTR2A | P28223 | 7/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 1.00 |
| ▸ | HTR1A | P08908 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | HTR2C | P28335 | 2/20 | 1.00 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 1.00 |
| ▸ | HTR3B | O95264 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gr-127935 SCHEMBL29462286 | 1.00 | HTR1D (1.00) | HTR1DHTR1BHTR2ASLC6A4MEN1 | |
| Gr-127935 SCHEMBL29657121 | 0.99 | MEN1 (1.00) | HTR1DHTR1BHTR2ASLC6A4MEN1 | |
| Gr-127935 SCHEMBL6017123 | 0.99 | MEN1 (1.00) | HTR1DHTR1BHTR2ASLC6A4MEN1 | |
| SCHEMBL7795147 | 0.95 | HTR1D (0.91) | HTR1DHTR1BHTR2ASLC6A4MEN1 | |
| SCHEMBL7795234 | 0.92 | HTR1D (0.84) | HTR1DHTR1BHTR2ASLC6A4MEN1 | |
| SCHEMBL7795310 | 0.91 | HTR1D (0.84) | HTR1DHTR1BHTR2ASLC6A4MEN1 | |
| SCHEMBL7795180 | 0.90 | HTR1D (0.81) | HTR1DHTR1BHTR2ASLC6A4MEN1 | |
| SCHEMBL7801411 | 0.89 | HTR1D (1.00) | HTR1DHTR1BHTR2ASLC6A4MEN1 | |
| SCHEMBL5318083 | 0.89 | HTR1D (0.80) | HTR1DHTR1BHTR2ASLC6A4MEN1 | |
| SCHEMBL7801017 | 0.88 | HTR1D (0.83) | HTR1DHTR1BHTR2ASLC6A4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS INC (US) | 2025-09-25 | — | — | US | claimed |
| WO-2023212244-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | claimed |
| US-20220146492-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | SHINE IAN BASIL (US) | 2022-05-12 | — | — | US | claimed |
| EP-3953000-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | Shine, Ian Basil (US) | 2022-02-16 | — | — | EP | claimed |
| EP-0760665-B1 | COMPOSITIONS CONTAINING 5HTIA AND 5HTID ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2001-12-12 | — | — | EP | claimed |
| EP-0533268-B1 | Benzanilide derivatives as 5-HT1D antagonists | GLAXO GROUP LTD (GB) | 2001-08-16 | — | — | EP | claimed |
| EP-0760665-A1 | COMPOSITION CONTAINING 5HT IA? and 5HT ID? ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1997-03-12 | — | — | EP | claimed |
| WO-1995031988-A1 | COMPOSITION CONTAINING 5HTIA and 5HTID ANTAGONISTS | SMITHKLINE BEECHAM P.L.C. (GB) | 1995-11-30 | — | — | WO | claimed |
| EP-0533268-A1 | Benzanilide derivatives as 5-HT1D antagonists | GLAXO GROUP LIMITED (GB) | 1993-03-24 | — | — | EP | claimed |
| JP-6116251-A | — | — | None | — | — | JP | disclosed |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS INC (US) | 2025-09-25 | — | — | US | disclosed |
| US-20240307414-A1 | METHODS AND MATERIALS FOR TREATING PROSTATE CANCER | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2024-09-19 | — | — | US | disclosed |
| CN-118600046-A | Molecular marker, detection reagent and method for breeding seven hundred-spotted cock and application of molecular marker and detection reagent | 广东海洋大学 | 2024-09-06 | — | — | CN | disclosed |
| US-20240100018-A1 | COMPOUNDS FOR THE TREATMENT OF A DISEASE OR DISORDER, METHODS FOR IDENTIFYING SAID COMPOUNDS | CEDARS-SINAI MEDICAL CENTER | 2024-03-28 | — | — | US | disclosed |
| EP-1098892-A1 | BIPHENYL DERIVATIVES | MERCK PATENT GmbH (DE) | 2001-05-16 | — | — | EP | disclosed |
| WO-2000005225-A1 | BIPHENYL DERIVATIVES | MERCK PATENT GMBH (DE) | 2000-02-03 | — | — | WO | disclosed |
| US-5510350-A | USEFUL IN TREATMENT OR PROPHYLAXIS OF DEPRESSION AND OTHER CENTRAL NERVOUS SYSTEM DISORDERS | GLAXO GROUP LIMITED (GB) | 1996-04-23 | — | — | US | disclosed |
| US-5340810-A | Useful in the treatment and prophylaxis of depression and other disorders of the central nervous system | GLAXO GROUP LIMITED (GB) | 1994-08-23 | — | — | US | disclosed |
| JP-H06116251-A | BENZANILIDE DERIVATIVE | GLAXO GROUP LTD | 1994-04-26 | — | — | JP | disclosed |
| EP-0533268-A1 | Benzanilide derivatives as 5-HT1D antagonists | GLAXO GROUP LIMITED (GB) | 1993-03-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | HTR2A, HTR5A, HTR6 | HTR1D 26/4885HTR1B 8/4885HTR2A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.